Skip to main content

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to September 2026.

37,204
Total recall recordsAll FDA and USDA recalls in Public Health Trace
9,841
Class I recallsReasonable probability of serious health consequences
24,366
Class II recallsTemporary or medically reversible health consequences
2,892
Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls
Most common hazardLack of Assurance of Sterility 2,073 recalls
Most affected stateHawaii 200 recalls mention this state

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters
Recall details
Location
Date range
Sort results
Clear filters
Metric
View
Recalls announced by month (Year to date)

A chart of recalls grouped by month.

Download CSV

Source: FDA and USDA public dataLast updated

Summary (Year to date)

  • 1,714 recalls have been announced year to date.
  • Sep 2026 was 3% higher than the previous complete period (Aug 2026: 182).
  • The highest complete period was Jun 2026 (297).
  • Oct 2026 is incomplete and not included in the figures above.
  • Complete data
  • Incomplete
Recalls by class

A bar chart of the total number of recalls in this dataset by recall class.

Recalls by class
ClassRecalls
Class II24,366
Class I9,841
Class III2,892
Not Yet Classified2
Download CSV
Recalls by class
ClassRecalls
Class II24,366
Class I9,841
Class III2,892
Not Yet Classified2

Showing 16,561–16,580 of 17,350 recalls

FDA Recall Ongoing Historical recordClass II

Alprostadil 2000 mcg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Adenosine-Mono-Phosphate Injection, 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Acepromazine 25 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Camila (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0715-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Folic Acid Injection, USP, 5 mg/mL, For IM, IV or SC Use, 10 mL, Multiple Dose Vial, Rx only, APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-184-11

by Fresenius Kabi USA, LLC

Reason
Failed Impurities/Degradation Specification
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Gentamicin Sulfate Injection USP 80 mg/2 mL(40 mg/mL as Gentamicin), 2 mL Single-dose Fliptop Vial, (NDC 0409-1207-13), Rx only, Manufactured by Hospira, Inc, Lake Forest, IL 60046 USA.

by Hospira Inc.

Reason
Presence of Particulate Matter: visible particles were identified floating in the primary container.
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial, Rx only, labeled as a) Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 60173, NDC 63323-970-02; and b) Manufactured in the USA for Nexus Pharmaceuticals Inc., Vernon Hills, IL 60061, NDC 14789-300-02

by Fresenius Kabi USA, LLC

Reason
Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Lessina(R) (Levonorgestrel and ethinyl estradiol tablets, USP) 0.1 mg/0.02 mg, 28 day regimen, Rx only, Barr Laboratories Inc., Pomona, NY --- NDC 0555-9014-67

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Published
July 17, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/5.0 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA 1910, NDC 0046-0975-11

by Pfizer Inc.

Reason
Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the specification for conjugated estrogens dissolution.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/2.5 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA, NDC 0046-0875-11

by Pfizer Inc.

Reason
Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the dissolution specification for conjugated estrogens.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Metronidazole Injection USP, RTU, 500 mg/100mL in Viaflex Plus Container, Baxter, Deerfield, IL 60015, NDC 0338-1055-48

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Sodium Chloride Injection, USP, a) Product code 2B1301- 50 mL in Viaflex Container Quad Pack (NDC 0338-0049-11); b) 2B1302- 100mL in Viaflex Quad Pack (NDC 0338-0049-18); c) 2B1306- 50 mL in Viaflex Single Pack (NDC 0338-0049-41; d) 2B1307- 100mL in Viaflex Single Pack (NDC 0338-0049-48); e) 2B1308- 50 ML in Viaflex Multi Pack (NDC 0338-0049-31); f) 2B1309- 100mL in Viaflex Multi Pack (NDC 0338-0049-38), Rx Only, Baxter, Deerfield, IL 60015

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Lidocaine Hydrochloride and 5% Dextrose Injection, USP, 2g VIAFLEX Plus Plastic Container, 500mL, Rx Only, Baxter, Deerfield, IL 60015

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterilty: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Heparin Sodium and 0.9% Sodium Chloride Injection, a) Product code 2B0944, 2000 USP Units, Viaflex Plus Container, 1000mL, (NDC 0338-0433-04), b) Product code 2B0953: 1000 USP Units, Viaflex Plus Container, 500 mL (NDC 0338-0431-03), Baxter, Deerfield, IL 60015

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

5% Dextrose Injection, USP, in VIAFLEX Plastic Container Multi Pack, Rx Only, a) 50 mL (NDC 0338-0017-31), b) 100 mL (NDC 0338-0017-38), Baxter, Deerfield, IL 60015

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

0.9% Sodium Chloride Injection, USP, in MINI-BAG Plus Container, a) 50 mL (NDC 0338-0553-11), b) 100 mL (NDC 0338-0553-18), Rx Only, Baxter, Deerfield, IL 60015

by Baxter Healthcare Corp.

Reason
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.
Published
July 10, 2013
Distribution
Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

0.9% Sodium Chloride Injection, USP, 50 mL Mini-Bag Plus Container, Rx only, distributed by Baxter Healthcare Corporation, Deerfield, IL 60015, USA, NDC 0338-0553-11

by Baxter Healthcare Corp.

Reason
Labeling Wrong Barcode; It may display wrong product code reflecting 0.9% Sodium Chloride Injection , USP 100 mL in MINI-BAG Plus container instead of 50 mL.
Published
July 3, 2013
Distribution
Nationwide

View recall →

Data last updated:

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.